N6-月桂酰虫草素 | 77378-06-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: N6-月桂酰虫草素
• 中文别名: 9-甲基-d3-腺嘌呤
• 英文名称: 3'-deoxy-N-(1-oxododecyl)adenosine
• 英文别名: N-lauroyl-cordycepin；3'-Deoxy-N6-lauroyladenosine；N-[9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]dodecanamide
• CAS: 77378-06-4
• 化学式: C₂₂H₃₅N₅O₄
• 分子量: 433.551
• InChiKey: SMLBNGQUSUEUEO-GSHUGGBRSA-N

物化性质

• 熔点：
  109-110°C
• 溶解度：
  可溶于氯仿、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  月桂酰氯 、 虫草素 在 吡啶 作用下， 以45.7%的产率得到N6-月桂酰虫草素
  参考文献：
  名称：

  Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain

  摘要：

  For slowing down the too fast metabolic velocity and increasing the bioavailability of cordycepin, four N-acyl-(propionyl-, octanoyl-, lauroyl- and stearoyl-) cordycepin derivatives were synthesized chemically and their pharmacokinetic profiles were investigated in this study. The results show that time of maximum concentration (T-max) and half-life (t(1/2)) would be elongated with the increase of the alkyl chain length, but maximum concentration (C-max) and area under concentration-time curve (AUC) increased initially, then decreased when the number of alkyl carbon exceeded eight. The T-max C-max and AUC of N-octanoyl-cordycepin were nearly 4, 30 and 68 times, respectively, higher than that of cordycepin. All derivatives could be transformed into cordycepin in vivo and the concentration of transformed cordycepin was proportional to that of derivatives. It indicated that N-octanoyl modification could decrease the metabolic velocity and increase the bioavailability of cordycepin to the maximum, thus it might be a promising prodrug of cordycepin. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.05.013

文献信息

• FAMIN ASSAY METHODS
  申请人：Cambridge Enterprise Limited

  公开号：EP3894580A1

  公开（公告）日：2021-10-20
• METHODS OF CANCER TREATMENT
  申请人：Cambridge Enterprise Limited

  公开号：EP3893897A1

  公开（公告）日：2021-10-20
• FAMIN Assay Methods
  申请人：Cambridge Enterprise Limited

  公开号：US20220017943A1

  公开（公告）日：2022-01-20

  This invention relates to the finding that FAMIN (fatty acid metabolism-immunity nexus ; LACC1, C13orf31)) is a trifunctional purine salvage enzyme that displays a unique combination of adenosine deaminase, purine nucleoside phosphorylase and methylthioadenosine phosphorylase activities. Methods of measuring FAMIN activity and screening for FAMIN modulators are provided that comprise determining the adenosine deaminase activity, purine nucleoside phosphorylase activity and/or methylthioadenosine phosphorylase activity of an isolated FAMIN protein.
• [EN] METHODS OF CANCER TREATMENT<br/>[FR] PROCÉDÉS DE TRAITEMENT DU CANCER
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2020120410A1

  公开（公告）日：2020-06-18

  This invention relates to the finding that inhibition or inactivation of FAMIN ('fatty acid metabolism– immunity nexus'; C13orf31; LACC1 (laccase domain containing 1))reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer orstimulating cell-mediated immune responsesin an individual byreducing FAMIN activity in the individual are provided. Also provided are methodsofactivating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering(a) a population of FAMIN deficient immune cells; or(b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.
• [EN] FAMIN ASSAY METHODS<br/>[FR] MÉTHODES DE DOSAGE FAMIN
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2020120406A1

  公开（公告）日：2020-06-18

  This invention relates to the finding that FAMIN (fatty acid metabolism-immunity nexus; LACC1, C13orf31)) is a trifunctional purine salvage enzyme that displays a unique combination of adenosine deaminase, purine nucleoside phosphorylase and methylthioadenosine phosphorylaseactivities. Methodsof measuring FAMIN activity and screening for FAMIN modulators are provided that comprise determining the adenosine deaminase activity, purine nucleoside phosphorylase activity and/or methylthioadenosine phosphorylase activityof an isolated FAMIN protein.